Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis.

Front Cardiovasc Med · 2020 · PMC7693545 · PMID 33304929

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

A prior meta-analysis of three RCTs (Hokusai VTE Cancer, SELECT-D, and ADAM VTE) assessed the efficacy and safety of DOACs in patients with CAT, and revealed borderline significant results for DOACs vs. dalteparin in terms of recurrent VTE (RR: 0.51, 95% CI: 0.25–1.03) and major bleeding (RR: 1.64, 95% CI: 1.00–2.69) ( 16 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.